NanoVac

New to NanoVac?

Hear from our experts in these recent blog posts.

The combination of Luna Labs’ delivery technology with our immunological expertise is opening up new possibilities in both infectious disease and cancer vaccine development.

Moriya Tsuji, MD, PhD Principal Investigator, Columbia University Aaron Diamond AIDS Research Center

Applying nanotechnology in medicine creates long-term benefits, improves the patient's life qualities, and reduces costs associated with treating preventable conditions.

Yang Xu, PhD Principal Investigator and NanoPharma Lead, Luna Labs

Because of the flexibility and speed at which we can customize payloads, we will be able to quickly adapt to hit the right target at the right time with the right treatment.

Chris Tison, PhD Director of Biotech, Luna Labs

Acceleration of mRNA Therapies

The importance of rapidly developing effective vaccines in response to emerging pathogens was demonstrated in the COVID-19 pandemic, with over 12 billion doses administered globally.

The current delivery method for mRNA vaccines, including for COVID-19, is lipid nanoparticles. They have known inflammatory reactions and are not designed to enhance the innate immune response.

In response to the need for flexible vaccine and therapeutic delivery technologies, Luna Labs has been developing delivery vehicles for mRNA and proteins since 2015.

NanoVac™ is the company’s short carbon nanotube-based platform that can safely and efficiently deliver a broad range of antigens and therapeutics via multiple administration routes.

Vaccination Against HIV-1

In collaboration with New York University and Columbia University, Luna Labs developed mRNA and protein-based HIV-1 vaccines and demonstrated their efficacy in humanized mouse models.

By mimicking virion size and optimizing its antigen, NanoVac is more effective at vaccinating compared to standard lipid nanoparticle-mRNA delivery.

NanoVac Vehicle

NanoVac Vaccine

NanoVac

Applications

The NanoVac platform is uniquely suited for addressing global health concerns and has potential integration into wider clinical applications to fight cancer, deliver therapeutics and more.

There are over 180 mRNA-based agents in pharma companies’ pipelines, and 80% of them are in the preclinical stage.

NanoVac provides and exciting opportunity to enhance their delivery, expand their method of administration beyond the intramuscular route, and reduce known inflammatory side effects with existing vehicles.